Stifel Nicolaus & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Stifel Nicolaus & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$257K	Buy	+2,216	New	+$243K	﹤0.01%	1233

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stifel Nicolaus & Co's ALXN Position: Q3 2013 in Review

Stifel Nicolaus & Co opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2013: 2,216 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings.

437 funds tracked by Wall St. Rank hold ALXN as of Q3 2013.

Stifel Nicolaus & Co held 2,216 shares of Alexion Pharmaceuticals worth $257K as of Q3 2013.
Alexion Pharmaceuticals was a new Stifel Nicolaus & Co position in Q3 2013.
Alexion Pharmaceuticals made up ﹤0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1233 holding.
437 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.